Pyramid Analytics and Smollan forge international partnership
22.8.2023 16:06:00 EEST | Business Wire | Press release
Global retail specialists Smollan have formalised an international reseller and implementation partnership agreement with next-generation decision and business intelligence (BI) software provider Pyramid Analytics. The agreement will see Smollan, via its data and technology business, DataOrbis, expanding its current service offering to include the ability to both sell Pyramid Analytics licenses and implement Pyramid Analytics software.
“Our clients operate in incredibly competitive industries, where the ability to make the best decision, quickly is the key to strong performance. Our hunt for a BI solution that delivers superior functionality, excellent value, and next-generation capability led us to Pyramid Analytics. We migrated the majority of our DataOrbis solutions onto their software last year, and already our clients are noticing a step-change in how we can help them capitalise on the explosive amount of data they have at their fingertips,” said James Collett, Smollan’s Chief Executive: Data & Technology.
The Pyramid Analytics partnership also provides DataOrbis with a growth opportunity geared at expanding DataOrbis’ services and footprint into verticals outside of the fast-moving consumer goods (FMCG) space where they have traditionally played. This is further supported by DataOrbis and Smollan’s global footprint, which includes operations in all major gateways.
“DataOrbis has an excellent understanding of what it takes to implement a successful data strategy across an organisation, regardless of industry. We are incredibly excited to be partnering with them internationally. By leveraging their global presence throughout their client and partner networks, I believe DataOrbis, together with Pyramid Analytics, can streamline and optimise their data analytics ecosystems to prepare them for what’s next. We are thrilled to have them on board,” said Omri Kohl, Pyramid Analytics CEO.
The Pyramid Platform consistently receives top ratings among leading analyst firms that evaluate business intelligence and analytics technologies. Most recently, Pyramid earned top rankings from Gartner in the 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
The Pyramid Platform consolidates data preparation, business analytics, and data science into a single, integrated, self-service platform that can be accessed by all levels of data users.
“The time it takes for a decision-maker to access data can make or break a company’s competitive advantage. Pyramid Analytics reduces the amount of time it takes users across the organisation to easily find the information they need without having to request it from IT. It’s a win-win for both users and overly stretched IT departments,” said Kohl.
Implementation is key to success
As the need to unlock the power of data has accelerated, businesses are realising the benefit of having one enterprise BI platform across the organisation, ensuring a single source of truth that can be safely, securely, and ethically managed. As an early adopter, DataOrbis has invested in creating and upskilling several Pyramid Analytics’ implementation teams working out of South Africa, India, and Slovenia to assist clients in creating and implementing their own unique global views. These teams, with over 50 certified Pyramid Analytics specialists, include senior resources with expertise across industries and geographies.
“The choice of BI platform is one part of the insights puzzle. The skill and time needed to implement the software is the next piece. In our experience, most companies don’t have these two vital resources readily available. By partnering with DataOrbis we can ensure the Pyramid Analytics software is expertly implemented and used to its fullest potential—all based on global best-practises. I am excited by the opportunities the Pyramid Analytics partnership will unlock for us and our clients,” said Collett.
ABOUT
Pyramid Analytics
Pyramid Analytics is the next generation of business analytics. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Analytics Platform operates directly on any data, enabling governed self-service for any person, and meeting analytical needs in a no-code environment without data extraction. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo. To find out more about Pyramid Analytics contact pr@pyramidanalytics.com.
Smollan
Founded in 1931, Smollan is a global commerce business, delivering growth for retailers and brand owners across five continents. Influencing what, when, where and shoppers browse and buy across multiple touchpoints, through Sales & Merchandising, Activation & Experience, Data & Technology and Digital Commerce. Internationally recognised for our exceptional human platform of over 75 000 people and our sophisticated systems, we drive sales and create brilliant shopper experiences for some of the world’s most loved brands. We are a global business that helps retailers and brands win at the point of purchase. Contact us at www.smollan.com.
DataOrbis
A leading data and technology company, DataOrbis uses its SMART ecosystem of services, solutions and technology to expertly help companies transform into businesses driven by data. With over 50 blue-chip clients, DataOrbis currently processes over 300 sources of data across 60+ countries in multiple languages. In 2020, DataOrbis joined forces with global retail specialist Smollan, increasing its ability to scale, expand and network globally.
DataOrbis is headquartered in South Africa with offices and partners across the globe. To find out more about DataOrbis contact us here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822485425/en/
Contact information
Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
E-Mail: pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
